One dose of cervical cancer vaccine may suffice, scientists say

A single dose of GlaxoSmithKline’s human papillomavirus (HPV) vaccine could prevent the majority of cervical cancers, saving money and improving uptake of a potentially life-saving vaccination, scientists said on Wednesday. GSK’s Cervarix, which targets two strains of HPV that cause about 70 percent of cervical cancers, is currently given in two- or three-dose schedules, but one dose seems to offer a similar level of protection. “Our findings question the number of HPV vaccine doses truly needed to protect the majority of women against cervical cancer, and suggest that a one-dose schedule should be further evaluated,” said Aimee Kreimer of the U.S. National Cancer Institute.
Sexual Health News Headlines – Yahoo! News